Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers

Sponsor
Saskatchewan Health Authority - Regina Area (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05557214
Collaborator
(none)
400
2
12

Study Details

Study Description

Brief Summary

Approximately 90% of antibiotics are prescribed in primary healthcare (PHC) in Canada (Public Health Agency of Canada, 2020), making this an important sector for antimicrobial stewardship. Upper respiratory tract infections (URTIs) represent a common indication in PHC for which antibiotics are often prescribed unnecessarily (Leis et al, 2020; Schwartz et al., 2020). Reducing unnecessary antibiotic treatment in this sector is a vital part of contributing to minimizing the global burden of antibiotic resistance.

The goal of this research project is to reduce the number of antibiotic prescriptions among family physicians identified as high prescribers in Saskatchewan. To achieve this, the investigators will send letters to the top 25th percentile of high prescribers in PHC. The letters will contain data indicating the prescribers high antimicrobial usage as well as guidance for reducing unnecessary prescriptions and promoting appropriate lengths of prescriptions for upper respiratory tract infections.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Audit and Feedback Letter
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Audit and Feedback Letter

This group will receive 2 audit and feedback letters and a study closure letter.

Behavioral: Audit and Feedback Letter
Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.

No Intervention: No Audit and Feedback Letter

This group will only receive a study closure letter.

Outcome Measures

Primary Outcome Measures

  1. Total Antibiotic Prescriptions [12 months]

    Total number of antibiotic prescriptions compared to covariate-adjusted baseline number of prescriptions prior to the intervention.

Secondary Outcome Measures

  1. Total Prolonged-Duration Prescription [12 months]

    Number of prescriptions longer than 7 days.

  2. Total Days of Therapy [12 months]

    Number of days of therapy of antimicrobials for each provider.

  3. Antibiotic Cost [12 months]

    Total cost of prescribed antibiotics.

  4. Total Specific Antibiotic Prescriptions [12 months]

    Number of prescriptions for specific antibiotics.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • must be a practicing family physician in Saskatchewan

  • top 25th percentile of antimicrobial prescribers

Exclusion Criteria:
  • fewer than 12 months of historical prescribing data available

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Saskatchewan Health Authority - Regina Area

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jason Vanstone, Research Scientist, Saskatchewan Health Authority - Regina Area
ClinicalTrials.gov Identifier:
NCT05557214
Other Study ID Numbers:
  • REB-22-38
First Posted:
Sep 27, 2022
Last Update Posted:
Sep 27, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jason Vanstone, Research Scientist, Saskatchewan Health Authority - Regina Area
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2022